NCT01557712 (KETADEP) is a Phase 3 clinical trial of ketamine venlafaxine in Major Depressive Disorder, sponsored by University Hospital, Grenoble.

Who is sponsoring NCT01557712?

NCT01557712 is sponsored by University Hospital, Grenoble.

What drugs are being tested in NCT01557712?

Interventions in NCT01557712: ketamine venlafaxine, Venlafaxine.

What condition does NCT01557712 study?

NCT01557712 studies Major Depressive Disorder.

Is NCT01557712 still recruiting?

NCT01557712 is currently completed. Last updated 23 February 2017.

Last reviewed 2017-02-23 · How we verify

NCT01557712: KETADEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six Weeks.

Completed Phase 3 Last updated 23 February 2017

What this trial tests

Phase 3 trial testing ketamine venlafaxine in Major Depressive Disorder in 25 participants. Completed in 1 January 2017.

Timeline

1 March 2012

Primary endpoint
1 January 2017

1 January 2017

Quick facts

Lead sponsor	University Hospital, Grenoble
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	triple
Primary purpose	treatment
Enrollment	25
Start date	1 March 2012
Primary completion	1 January 2017
Estimated completion	1 January 2017
Sites	1 location across France

Drugs / interventions tested

ketamine venlafaxine — full drug profile →
Venlafaxine — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

University Hospital, Grenoble

Who can join

18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Depressive state
Time frame: 6 weeks
Assessment of depression by MADRS defining six weeks: * the state of clinical response defined by a MADRS score less than 50% in MADRS score at baseline initial set. * the state of clinical remission is defined by obtaining a MADRS score ≤ 8.

Sponsor's own description

The objective of this study is to evaluate the effectiveness of ketamine (infusion of 0.5mg/kg) and venlafaxine compared to the use of venlafaxine alone in the treatment of major depression (MADRS score ≥ 20 ) to six weeks of treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL, Hurducas C, Hawton K, Spyridi S, et al · · 2021 · cited 52× · PMID 34510411 · DOI 10.1002/14651858.cd011612.pub3

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other University Hospital, Grenoble trials

Trials by the same sponsor.

NCT07479225 — Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study · NA · not yet recruiting
NCT07477613 — Implantable Brain-Computer Interface for Upper-Limb Recovery After Stroke · NA · not yet recruiting
NCT07379372 — Bladder Overactivity and Post-Botulinum Toxin Telemonitoring · NA · not yet recruiting
NCT07166991 — Anesthesia sTrategy foR Organ Procurement In braiN dEath · Phase 3 · recruiting
NCT07367880 — The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01557712 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Grenoble
Last refreshed: 23 February 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01557712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing